Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00420212 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

A Phase 3 study of Relapsing Remitting Multiple Sclerosis, sponsored by Biogen.

Completed
Registry status
Phase 3
Development phase
1,234
Enrollment target
20
Study locations

NCT00420212 is a Phase 3 study of Relapsing Remitting Multiple Sclerosis that has completed, run by Biogen. The registered enrollment target is 1,234 participants, above the 153-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (707% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00420212, a Phase 3 study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 3
Development phase
1,234 participants
Enrollment target
20
Study locations

Study Summary

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.

Conditions Studied

Relapsing Remitting Multiple Sclerosis

Interventions

  • DRUG Placebo
  • DRUG BG00012

Study Locations (20)

Massachusetts

  • Research Site - Brighton
  • Research Site - Hopedale
  • Research Site - Lexington
  • Research Site - Springfield
  • Research Site - Worcester

Arizona

  • Research Site - Gilbert
  • Research Site - Phoenix

Illinois

  • Research Site - Evanston
  • Research Site - Palos Heights

Indiana

  • Research Site - Fort Wayne
  • Research Site - Indianapolis

California

  • Research Site - San Francisco

Connecticut

  • Research Site - New Haven

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Vero Beach

Trial Details

FieldValue
Enrollment Target 1,234 participants
Start Date 2007-01
Est. Completion 2011-02
Phase Phase 3

Sponsor

Biogen

334 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00420212

The ClinicalTrials.gov registry entry for NCT00420212 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,234 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (707% higher). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00420212 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT00420212 about?

NCT00420212 is a clinical study titled "Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis". To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get wors...

What is the current status of trial NCT00420212?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,234 participants. The study started on 2007-01. Estimated completion is 2011-02.

What conditions does trial NCT00420212 study?

This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.

What interventions are being tested in trial NCT00420212?

The interventions under investigation include: Placebo (DRUG), BG00012 (DRUG).

Who is sponsoring clinical trial NCT00420212?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00420212 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Remitting Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Remitting Multiple Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.